Mean fluorescence intensity (MFI) of SIGLEC1 expression before and after introduction of prednisolone or hydroxychloroquine. Mean fluorescence intensity.

Slides:

Advertisements

Similar presentations

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Advertisements

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Main fields of interest.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Percentage of patients achieving EULAR response

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Endochondral bone formation in HLA-B27 transduced ATDC5 micromasses.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

Frequency of patients in flare at each time point over 3 months

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

Conventional treatment to prevent obstetric complications during pregnancy. *Antiphospholipid (aPL) antibody carriers: individuals with aPL positivity.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Three different reconstructions after one single mDixon sequence of

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

The identification of leucocyte subset-specific type 1 interferon (IFN-1) modules. The identification of leucocyte subset-specific type 1 interferon (IFN-1)

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Box plot showing median cytokine levels and IQRs for (A) IP-10, (B) TNF-α, (C) LT-α and (D) IFN-γ in controls and pSS fatigue groups. Box plot showing.

Core type 1 interferon (IFN-1)-associated genes are more highly expressed in myeloid subsets. Core type 1 interferon (IFN-1)-associated genes are more.

DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.

IFN and neutrophil gene expression studies.

2/A Comparison of IP-10 and SIGLEC1 levels in healthy donors (HD), patients with glandular (gl.) and extraglandular (egl.) pSS and SLE 2/A. 2/A Comparison.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Osteogenesis in monolayer HLA-B27 transduced hPDCs.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Hypothetical model of fatigue in a chronic immunological condition.

Maximum mean (SE) per cent change in serum urate from baseline (Emax) following once-daily oral administration of varying verinurad doses in combination.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

(A–D). (A–D). B-cell and Ig changes. Mean changes in total CD3-CD20+ B-cells (A) and immunoglobulin (Ig) subclasses levels (B-D) were measured over 24 weeks.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

ACR responses: (A) responses at Week 52 and Week 104

Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Subject disposition through week 156 of treatment

Mean (SE) maximum urinary uric acid excretion rate (mg/hour) following verinurad doses in combination with febuxostat 40 or 80 mg vs febuxostat 40 or 80 mg.

Patient disposition after 2 years of treatment.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.

Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Achievement of MDA over 144 weeks.

Flowchart of literature revision to identify current available clinical practice guidelines (CPGs) specifically addressed to Ehlers-Danlos Syndromes (EDS)

Classification tree with the selected characteristics.

(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.

(A) Mean NMR spectra of patient sera show differences in metabolite intensities between responders and non-responders before (a) and 6 months after (b)

Joint pain location and severity.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

Kaplan-Meier estimate of drug continuation until discontinuation for tocilizumab, canakinumab, anakinra and etanercept, as a first biological agent for.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.

NRDC and TNF-α increase in synovial fluid from patients with RA

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

Mean fluorescence intensity (MFI) of SIGLEC1 expression before and after introduction of prednisolone or hydroxychloroquine. Mean fluorescence intensity (MFI) of SIGLEC1 expression before and after introduction of prednisolone or hydroxychloroquine. In a separate cohort, the MFI of SIGLEC1 on CD14+ monocytes of patients with either SLE (shown in black) or pSS (shown in red) was measured before and after the introduction of prednisolone or hydroxychloroquine. The average dose was 13.33 mg for prednisolone and 300 mg for hydroxychloroquine; the time period between measurements was ∼5.5 months for prednisolone and 5 months for hydroxychloroquine. Both treatments significantly reduced SIGLEC1 expression (p=0.028 and p=0.046, Wilcoxon test). The dashed line represents the calculated threshold of SIGLEC1 (260.5). pSS, primary Sjögren's syndrome; SIGLEC1, sialic acid binding Ig like lectin 1; SLE, systemic lupus erythematosus. Thomas Rose et al. RMD Open 2016;2:e000292 Copyright © BMJ Publishing Group & EULAR. All rights reserved.